This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE

Title Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE
Abstract

A new series of donepezil-tacrine hybrid related derivatives have been synthesised as dual acetylcholinesterase inhibitors that could bind simultaneously to the peripheral and catalytic sites of the enzyme. These new hybrids combined a tacrine, 6-chlorotacrine or acridine unit as catalytic binding site and indanone (the heterocycle present in donepezil) or phthalimide moiety as peripheral binding site of the enzyme, connected through a different linker tether length. One of the synthesised compounds emerged as a potent and selective AChE inhibitor, which is able to displace propidium in a competition assay. These results seem to confirm the ability of this inhibitor to bind simultaneously to both sites of the enzyme and make it a promising lead for developing disease-modifying drugs for the future treatment of Alzheimer's disease. To gain insight into the molecular determinants that modulate the inhibitory activity of these compounds, a molecular modelling study was performed to explore their binding to the enzyme.

Apa Reference Alonso, D., Dorronsoro, I., Rubio, L., Muñoz, P., García-Palomero, E., Del Monte, M., Bidon-Chanal, A., Orozco, M., Luque, F. J., Castro, A., Medina, M., & Martínez, A. (2005). Donepezil–tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorganic & Medicinal Chemistry, 13(24), 6588–6597. 10.1016/j.bmc.2005.09.029
Doi 10.1016/j.bmc.2005.09.029
Publication Date Dec 2005
Publication Type Article
Researcher Ana Martínez
Ontology Drug Discovery and design, Molecular Interactions/Docking
Research Groups Translational Medicinal and Biological Chemistry
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home